1,000 Layoffs Expected At Novo Nordisk As US Pricing Pressures Bite
Executive Summary
As a parting gift to Novo Nordisk staff, outgoing CEO Lars Rebien Sørensen has announced 1,000 job cuts at the company – around half in its home country of Denmark – in order to create a "sustainable balance between income and costs" in preparation for a challenging 2017.
You may also be interested in...
Novo Nordisk Shakes Up R&D Strategy To Cope With US Pricing Pressures
Increasing competition and pricing pressures in the US, have led Novo Nordisk to halve its profit growth expectations for 2017. In response, the diabetes drug developer plans to double-down on R&D efforts, expand into new therapy areas and seek external deals for early-stage assets to bulk up its pipeline.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.